---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024224"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:56:11.956699+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma names Timothy Lorber as CFO; Vander Hoek shifts to VP Regulatory

## Summary
- Timothy Lorber, CPA with 40+ years experience, appointed CFO; part-time until Sept 9, 2024, then full-time from Sept 10, 2024.
- Lorber receives $227k annual base salary; 227,635 RSUs vesting over 3 years; eligible for up to $72k milestone bonus.
- Current CFO Michael Vander Hoek transitions to full-time Vice President, Regulatory concurrent with Lorber's full-time appointment.
- Vander Hoek had served as both CFO and VP Regulatory for past four years; will now focus on regulatory matters for Phase 2 trial.

## SEC filing metadata
- accession: 0001493152-24-024224
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024224
- JSON: https://secwatch.observer/filing/0001493152-24-024224.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024224.txt

## Source-grounded claims
- claim_id: 8fa0a96d9d
  claim: Timothy J. Lorber was appointed as Chief Financial Officer at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm
- claim_id: 9315dc2132
  claim: Michael Vander Hoek changed role as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.